Source: International Congress 2019 – Metabolic alterations as a driver of chronicity in lung disease



Rating:

Share or cite this content

Citations should be made in the following way:
R. Chambers (London, United Kingdom). Targeting metabolic reprogramming as a novel anti-fibrotic strategy. International Congress 2019 – Metabolic alterations as a driver of chronicity in lung disease

Member's Comments

No comment yet.

Related content which might interest you: How to disrupt malicious LC-fILD pathways: antifibrotic agents as a promising therapeutic approach Source: Virtual Congress 2021 – Lung cancer and fibrotic interstitial lung diseases: a challenging association for pulmonologists Year: 2021 Targeting the arginase pathway: potential developments as new avenues for treatment Source: Annual Congress 2004 - Arginase: a novel target and marker for asthma? Year: 2004 Reversing glucocorticoid resistance as a new therapeutic strategy Source: Annual Congress 2012 - The promise of new drugs for treating asthma and COPD Year: 2012 Does acute and persistent metabolic dysregulation in COVID-19 point to novel biomarkers and future therapeutic strategies? Source: Eur Respir J, 59 (2) 2102417; 10.1183/13993003.02417-2021 Year: 2022 The promise of mTOR signaling as a therapeutic target for IPF Source: Virtual Congress 2020 – Reflections from the Lung Science 2020 conference Year: 2020 Targeting AMPK and the Nrf2/HO-1 axis: a promising therapeutic strategy in acute lung injury Source: Eur Respir J, 58 (6) 2102238; 10.1183/13993003.02238-2021 Year: 2021 Targeting intermittent hypoxia downstream pathways for biomarker discovery and new treatment perspectives in cutaneous melanoma Source: Eur Respir J, 53 (2) 1802444; 10.1183/13993003.02444-2018 Year: 2019 Late Breaking Abstract - Anti-inflammatory activity of novel transtilbene sulfonamide analogues as potential novel therapeutic agents for inflammatory lung disease Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies Year: 2019 Gene expression profiling: identifying novel gene targets for therapeutic intervention Source: Annual Congress 2008 - PG8 - Cellular and molecular technologies of today - treatments of tomorrow Year: 2008 Genetic studies as a tool for identifying novel potential targets for treatment of COPD Source: Eur Respir J, 50 (5) 1702042; 10.1183/13993003.02042-2017 Year: 2017 Targeting neuropeptide receptors by substance-P analogues identifies a strategy to develop novel anti-cancer therapies Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008 Interleukin-6: potential new function and regulation through alternative splicing Source: Eur Respir J 2001; 18: Suppl. 33, 476s Year: 2001 In vitro pharmacological characterization of a novel p38α (MAPK14) inhibitor designed for inhaled delivery Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016 When and how to identify resistance mechanisms to targeted therapies Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019 Targeting EGFR signalling in chronic lung disease: therapeutic challenges and opportunities Source: Eur Respir J 2014; 44: 513-522 Year: 2014